A single injection of the drug lepodisiran slashed a key heart risk factor, lipoprotein(a), by 94% for six months, offers hope for treating a genetic cause of heart disease.
CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points ...
In the first human trial of a new therapeutic, a single injection of lepodisiran reduced levels of lipoprotein(a), or Lp(a), to undetectable levels for nearly one year, according to late-breaking ...
Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular events in initially healthy women. Subscribe to our newsletter for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results